GSK India Q2 FY27 Revenue ₹1180 Cr, PAT ₹335 Cr
GlaxoSmithKline Pharmaceuticals Ltd (GSK India) reported strong financial results for the second quarter and half-year ended 30th September 2026. Revenue for the quarter reached INR 1180 crore, a 21% year-on-year increase. Profit After Tax (PAT) grew by 31% to INR 335 crore, with EBITDA up 20%. The company saw robust growth across its General Medicines, Vaccines, and Specialty Medicines portfolios, driven by new product introductions and strong performance of key brands like Augmentin and Calpol. The Oncology business, including Jemperli and Zejula, is gaining momentum, with plans to launch BLENREP for multiple myeloma. GSK India is also focusing on supply chain resilience and expanding its adult vaccination market with Shingrix.
Key Highlights
- Q2 FY27 revenue up 21% YoY to ₹1180 crore.
- PAT increased 31% to ₹335 crore; EBITDA grew 20%.
- Strong performance in General Medicines, Vaccines, and Specialty portfolios.
- Oncology portfolio momentum continues; BLENREP to launch.
- Focus on supply chain resilience and adult vaccination growth.
Price Impact
More from GLAXO